2026 Growth Plan
Driving innovation and expanding global presence with diversified medical solutions.
Strengthening presence in North America, Europe, and Australia through FDA 510(k) and CE certifications, and entering major U.S. GPO contracts (e.g., Vizient, Premier). Supported by our Taiwan-based facility, annual supply will exceed 40 million sets to meet global demand, including expansion into emerging markets.
Positioned to capture the growing global PPE market with agile, locally integrated supply chains. Classified as FDA Class II medical devices, undergoing 510(k) and CE clearance. Focus on U.S. and European GPO contracts, with partnerships in Australia for hospital and long-term care markets.
Targeting hospitals and long-term care facilities worldwide, with major channels including Cardinal Health and McKesson in North America, and large hospital groups in Europe and Australia. Products emphasize absorbency, comfort, and cost-effectiveness to serve the needs of an aging population.
Targeting hospitals and long-term care facilities worldwide, with major channels including Cardinal Health and McKesson in North America, and large hospital groups in Europe and Australia. Products emphasize absorbency, comfort, and cost-effectiveness to serve the needs of an aging population.
Maintaining 30 million units annually as the cornerstone of
Kenyen Group
’s revenue. Strengthening long-term client partnerships while exploring Southeast Asia expansion. Marketing strategy focuses on service, technical support, and bundled value offerings.
Launching
Kenyen Group’s own brand of female hygiene wipes and eye-care wipes for pharmacies, supermarkets, and online retail. Featuring natural ingredients, safety, and dermatological testing. 2025 milestones include finalizing formulation, packaging, and achieving stable mass production.